By Fineline Cube 
UCB (EBR: UCB) announced today Week 16 data from the BE BOLD Phase III clinical trial demonstrating statistically superior ACR50 joint outcomes for BIMZELX (bimekizumab) compared to SKYRIZI (risankizumab) in adults with active psoriatic arthritis (PsA). The dual IL-17A/F inhibitor achieved its primary endpoint with 49.1% of patients reaching ACR50 response versus 38.4% for risankizumab (p=0.0078).
Clinical Trial Results
| Endpoint | BIMZELX (bimekizumab) | SKYRIZI (risankizumab) | Statistical Significance |
|---|---|---|---|
| ACR50 at Week 16 | 49.1% | 38.4% | p=0.0078 |
| Trial Design | Randomized, head-to-head | Active comparator | Superiority demonstrated |
| Patient Population | Adults with active PsA | Same population | Primary endpoint met |
Drug Profile & Mechanism of Action
- Molecule: Humanized monoclonal IgG1 antibody
- Target: Dual selective inhibition of interleukin 17A (IL-17A) and interleukin 17F (IL-17F)
- Innovation: First and only dual IL-17A/F inhibitor approved for multiple inflammatory conditions
- Current US Approvals: Psoriasis, psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa
- Differentiation: Simultaneous blockade of both IL-17A and IL-17F provides broader pathway inhibition compared to selective IL-17A or IL-23 inhibitors
Competitive Landscape Analysis
| Product | Mechanism | PsA Indication | Key Differentiator |
|---|---|---|---|
| BIMZELX | Dual IL-17A/F inhibitor | Approved | Superior ACR50 response in head-to-head trial |
| SKYRIZI | IL-23 inhibitor | Approved | Established efficacy profile |
| Other IL-17 Inhibitors | Selective IL-17A | Approved | Single pathway blockade |
The BE BOLD trial represents the first direct head-to-head comparison between a dual IL-17A/F inhibitor and an IL-23 inhibitor in psoriatic arthritis, providing critical comparative efficacy data for treatment selection.
Market Impact & Commercial Implications
- PsA Treatment Market: Global psoriatic arthritis therapeutics market projected to reach $8.2 billion by 2028, with biologics representing the fastest-growing segment
- Competitive Advantage: Superior ACR50 response rate provides compelling differentiation in a crowded biologic landscape
- Payer Considerations: Head-to-head superiority data may support premium pricing and favorable formulary positioning
- Physician Adoption: Dual mechanism of action combined with superior efficacy could accelerate uptake among rheumatologists seeking optimal joint outcomes
- Pipeline Validation: Results reinforce UCB’s strategic focus on dual cytokine inhibition as a superior therapeutic approach for inflammatory diseases
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial results, regulatory approvals, and commercial expectations for BIMZELX. Actual results may differ materially due to risks including post-marketing safety findings, competitive dynamics, and payer reimbursement decisions.-Fineline Info & Tech